Abstract. The ATP-binding cassette transport proteins (ABC transporters) represent important determinants of drug excretion. Protective or excretory tissues where these transporters mediate substrate efflux include the kidney proximal tubule. Regulation of the transport proteins in this tissue requires elaborate signaling pathways, including genetic, epigenetic, nuclear receptor mediated, posttranscriptional gene regulation involving microRNAs, and non-genomic (kinases) pathways triggered by hormones and/or growth factors. This review discusses current knowledge on regulatory pathways for ABC transporters in kidney proximal tubules, with a main focus on P-glycoprotein, multidrug resistance proteins 2 and 4, and breast cancer resistance protein. Insight in these processes is of importance because variations in transporter activity due to certain (disease) conditions could lead to significant changes in drug efficacy or toxicity.
INTRODUCTION
The kidneys largely contribute to the urinary excretion of drugs and metabolic waste products not only by filtering the blood from these potentially harmful compounds but also by contributing to their active tubular secretion. Therefore, the kidney proximal tubules possess a variety of transporters that cooperate in basolateral uptake and luminal secretion. Clinically, these xenobiotic transporters are often involved in significant interactions, which lead to unforeseen changes in drug plasma levels, uremia, and/or nephrotoxicity (1, 2) . Drugs may also interact with endogenous substrates and food components, leading to similar effects. In addition, the expression of transport systems and/or their function can be affected by disease circumstances. Under such conditions, xenobiotics and waste products produced can accumulate due to tubular dysfunction sometimes leading to a progression of kidney failure. Data obtained from animal models and human diseases showed that the expression level of drug transporters is tightly controlled as a key adaptation mechanism to such stress conditions (3) . Insight in these mechanisms may provide therapeutic targets for clinical interventions in acute toxicity. In this issue of the AAPS Journal, the uptake transporters are described in other reviews, whereas here the function and regulation of an important class of efflux pumps belonging to the ATP-binding cassette (ABC) family of transporters are being discussed. The secretion of compounds into the urinary compartment via efflux transporters at the proximal tubule apical membrane is unidirectional and predominantly (but not exclusively) mediated by the ABC transporters.
The ABC protein family comprises a large number of transmembrane proteins expressed in almost all organisms ranging from prokaryotes to humans. ATP hydrolysis reveals the energy required for the translocation of substrates, for which each full transporter contains two cytoplasmic binding domains. The human ABC transporter family consists of 49 members divided in seven subfamilies ranging from A to G based on sequence and organization of the ABC domain(s) similarities. Members of the B, C, and G subfamilies have been associated with renal drug transport ( Fig. 1) (1,2 ). Up to 20 ABC genes have, as yet, been linked to inherited diseases, including Tangier disease (ABCA1), sitosterolemia (ABCG5 or ABCG8), Dubin-Johnson syndrome (ABCC2), pseudoxanthoma elasticum (ABCC6), cystic fibrosis (ABCC7), and hyperinsulinemic hypoglycemia of infancy (ABCC8) (4) . For disease modeling and/or drug target identification, ABC transport protein knockout animal models have offered considerable insights into the characteristics and function of the individual efflux pumps (see, e.g., (5, 6) ).
This review focuses on ABC proteins as xenobiotic efflux pumps in the kidney. These include P-glycoprotein (P-gp; ABCB1), the multidrug resistance (MRP)-associated protein family (MRP1-9, ABCC1-6, and ABCC10-12), and breast cancer resistance protein (BCRP; ABCG2). Moreover, the physiological and pathological regulatory pathways for P-gp, MRP2, MRP4, and BCRP, which are abundantly present in the contemplated tissue and mostly relevant for renal drug handling, are being discussed.
LOCALIZATION AND FUNCTION OF ABC TRANSPORTERS IN THE KIDNEY P-glycoprotein
The best-characterized ABC transporter concerns P-gp, which was originally discovered for its over-expression in drug-resistant tumor cells. But later, the efflux pump was recognized as a crucial component of barrier tissues and a significant factor in drug disposition. In the kidney, expression of P-gp is confined to the proximal tubule apical membrane (9), a localization in agreement with a urinary efflux function. The resolved X-ray structure of mouse P-gp allows homology modeling by which insight into substrate handling can be obtained (10) . P-gp has a preference for uncharged and cationic compounds. P-gp confers resistance not only to chemotherapeutics but also to a large number of other clinically and toxicologically relevant compounds (11) . The problem of multidrug resistance is clinically counteracted by blocking P-gp function with compounds usually acting as competitive inhibitors (see for overview (11, 12) ). More specific substrates were identified using P-gp-deficient mice, the Mdr1a/1b( −/− ) mice. Unlike humans, rodents contain two genes encoding for the efflux pump, Mdr1a and Mdr1b. Although no obvious phenotype, except for a larger susceptibility to neurotoxic drugs, was discovered in these mice at first sight (5), careful characterization revealed altered gastrointestinal and renal phenotypes. Spontaneous development of colitis and signs of severe chronic inflammation of the gut have been reported for Mdr1a-deficient mice when kept under specific pathogen-free conditions. Presumably, this was caused by defects in the epithelial cells lining the gut (13) . More recently, a comparable phenotype in humans, associated with ABCB1 gene variants, was reported (14) .
In the kidney, P-gp was reported to be inducible. After transplantation, an increased P-gp expression in renal tubule apical membrane was observed in patients treated with the immunosuppressive calcineurin inhibitor, cyclosporine A. However, patients with a 3,435 C−>T ABCB1 variant showed a higher sensitivity to nephrotoxicity associated with cyclosporine A therapy, possibly due to reduced apical expression of P-gp (15, 16) . Such mutations do not always lead to renal function problems but can have systemic effects as well. Recently, an association between ABCB1 polymorphisms and the resistance against steroid treatment of nephrotic syndrome in children was found (17) , suggesting a gain of function in P-gp. In addition, we showed that the P-gpdeficient mice (Mdr1a/1b( −/− )) exhibit a generalized disturbed renal tubular function caused by decreased intracellular levels of ATP and altered morphology of mitochondria (18) . This proximal tubular dysfunction showed prominent resemblances with renal Fanconi syndrome, with a diminished reabsorption of amino acids and low molecular weight proteins. In a further attempt to study the role of the efflux pump in tubular dysfunction, we investigated its role in the autosomal recessive disorder, cystinosis (19) , which is associated with the development of renal Fanconi syndrome. We used conditionally immortalized proximal tubular epithelial cells obtained from urine from cystinotic patients Fig. 1 . Localization of ABC transporters in the kidney and examples of their substrates. Note that P-gp, MRP2, MRP4, and BCRP are most important in renal drug handling and contribute to active tubular secretion and are localized at the proximal tubule (PT). Other nephron segments include thick ascending limb of Henle (TAL), distal tubule (DT), and collecting duct (CD). For details on specific substrates, the reader is referred to recently published reviews (2, 7, 8) and healthy volunteers. No differences in the functional expression of P-gp was found in cystinotic cells as compared with controls; however, inhibition of P-gp activity in control or cystinotic proximal tubular cells resulted in decreased uptake of phosphate, in agreement with the phenotype of P-gp-deficient mice and with that of patients with cystinosis (20) .
Multidrug Resistance Proteins
Out of the nine MRP protein (ABCC) members, MRP2 and MRP4 are the most important drug efflux pumps in the kidney. Details on the function and role of MRPs can be found in previous reviews from our group and others (e.g., (2, 7, 21) ). The MRPs mediate the transport of a wide variety of preferentially, but not exclusively, organic anions, including phase II metabolism products (2,7). MRP1 (ABCC1) is not expressed in the kidney proximal tubule but localizes to the basolateral membranes of the limb of Henle cells and the distal and collecting duct tubule cells (21) , where it possibly protects against accumulating toxic compounds that can reach high concentrations due to hormone-controlled water reabsorption. In support, Abcc1 knockout mice developed polyuria and acquired nephrogenic diabetes insipidus when treated with etoposide (22) .
There is an overlapping substrate specificity of MRP2 with that of MRP1 and MRP3, consistent with the high amino acid homology between these MRPs. Patients with DubinJohnson syndrome have a defect in MRP2, characterized by an impaired canalicular secretion of glutathione, glutathione conjugates, and bilirubin glucuronides. Two rat strains, the Groningen yellow/transport-deficient (GY/TR − ) Wistar rat and the Esai hyperbilirubinaemic Sprague-Dawley rat (EHBR), are presented with a similar phenotype due to MRP2 deficiency (as reviewed in (21)). Also, the renal efflux of some larger MRP2 substrates was found to be impaired in the GY/TR − rat (23). MRP3 (ABCC3) is expressed to a minor extent in the distal convoluted tubule basolateral membranes and, probably, cells lining the thick ascending loop of Henle (see for details (21) ). In contrast, rat kidneys express Mrp3 in the basolateral membrane of proximal tubule cells. The efflux pump was found to be upregulated in hepatocytes of patients with the Dubin-Johnson syndrome, in agreement with MRP3 expression in EHBR rats that showed increased levels in the kidney as well. These findings suggest that MRP3 may function as a compensatory mechanism in MRP2 deficiency to reduce injury from accumulating toxic components, such as bilirubin glucuronide.
MRP4 shows a high expression in the kidney, where the efflux pump is expressed in the proximal tubule apical membrane (24) . The wide range of drug substrates includes antibiotics, antivirals, and diuretics (8) . In comparison to MRP2, MRP4 exhibits a higher expression in the kidney and a higher affinity for smaller organic anions (25) . Polymorphisms in ABCC2 and ABCC4, leading to diminished MRP2 or MRP4 activity, respectively, are associated with increased sensitivity to nephrotoxicity or delayed graft function after kidney transplantation (26, 27) . MRP5 (ABCC5) is ubiquitously expressed and located at the basolateral membrane in polarized epithelial cells (as reviewed in (21)). Like MRP4, MRP5 transports nucleoside and nucleotide drugs. The expression and localization of MRP5 along the nephron has yet to be determined.
MRP6 (ABCC6) is highly expressed in kidney and liver as compared with other tissues (as reviewed in (21)). In human and mouse kidney, the efflux pump is found in the cells lining the proximal tubules where the protein is localized to the basolateral plasma membrane and, to a lesser extent, in distal tubule cells of mouse. ABCC6 gene mutations or deletions were reported in patients suffering from pseudoxanthoma elasticum, a rare inherited connective tissue disease. Vitamin K was suggested as MRP6 substrate and essential element in this disease (28) , but this hypothesis was recently rejected (29) . Therefore, the physiological substrates of MRP6 potentially involved in pseudoxanthoma elasticum still need to be identified.
Although expression of MRP7 (ABCC10) seems low in human tissues (as reviewed in (21)), a recent study showed that polymorphisms in ABCC10 are associated with tenofovir-induced renal tubular toxicity (30) . This suggests renal tubular apical membrane expression, which need to be proven. The localization and function (if any) of MRP8 (ABCC11) and MRP9 (ABCC12) in the kidney, also need to be confirmed. BCRP BCRP (ABCG2) was found to be localized at the apical surface of human proximal tubule cells (31) . Gene expression analysis revealed also renal expression of Abcg1, Abcg5, and Abcg8, associated with the cholesterol transport (32); however, BCRP is the only member of the subfamily G proven to be involved in drug transport and not in cholesterol efflux. Hence, the activity of the efflux pump may be influenced by cholesterol through the plasma membrane lipids composition and a physical interaction between caveolin-1 and BCRP (33) . G subfamily members are half-transporters, which need to homo-or heterodimerize to become a fully active efflux pump. A vast array of BCRP substrates have been identified, including small and large organic anions, uncharged or amphiphilic compounds. Abcg2 knockout mice showed lethal phototoxicity when subjected to an alfalfa-containing diet. This was attributed to pheophorbide A retention, indicating that BCRP excretes porphyrins (34) . Besides, BCRP plays a role in the transport of or interactions with androgens, estrogens, and phytoestrogens (35) .
A single nucleotide polymorphism (SNP) in ABCG2 was reported to be associated with increased systemic urate concentrations due to reduced urinary urate transport (36) . Hyperuricemia coincides with features of gout, metabolic syndrome, and with cardiovascular and renal disease, which often results from urate-induced inflammatory and oxidative damage. In contrast, elevated plasma urate levels may be protective by the free radicals scavenging properties of the nitrogenous end product. For maintaining plasma urate at physiological levels, proper function of multiple renal transport proteins, including BCRP and MRP4, is a prerequisite (3, 37) . Often, SNPs result in a loss of function through affecting protein stability or by alterations in targeting the protein towards the plasma membrane. In contrast, also SNPs have been reported that resulted in a gain of function (38) . With respect to ABC transporters in renal proximal tubule, the latter most likely contributes to reduced risk of tubulotoxicity but can have important pharmacodynamic effects.
ABC TRANSPORTER REGULATION IN KIDNEY PROXIMAL TUBULES
Clearly, distinct pathways are concerned with the regulation of ABC transporters, comprising genomic (genetic, epigenetic, and nuclear receptor mediated) pathways and non-genomic (kinases and the new emerging field of posttranscriptional target repression by microRNAs) regulation, triggered by hormones, growth factors, and exogenous factors, for which the time span of exposure and the stressor determine the effect. Additionally, the expression levels of transport proteins and their function can be altered by disease conditions, including renal or liver failure and inflammation. Although information on ABC transporter regulation in the kidney is sparse, the regulatory pathways revealed are discussed in more detail in the following sections, details of which can be found in Table I . An overview of potential mechanisms involved in genomic and non-genomic pathways in ABC transport protein regulation is presented in Fig. 2 .
Hormonal Regulation of ABC Transporters

Steroid Hormones
A few studies reported gender differences with respect to ABC transporter abundancy, suggesting a role for steroid hormones in their regulation. Abcb1b, but not Abcb1a, gene expression is somewhat higher in females than in male mice kidneys (39) . This was confirmed for P-gp in rat livers, but not in kidneys, and after testosterone treatment P-gp levels in females reduced to male rat liver levels (40) . The same study showed a similar effect on Mrp2 in rat livers, whereas Abcc2 gene expression levels were comparable in female and male kidney (39) . For Mrp4, female predominant appearance is observed in murine kidney and liver (41) . This contradicts to findings for rat where Mrp4 is more abundantly present in male than in female kidneys (42) . Gonadectomy resulted in equal Mrp4 levels in male kidneys as compared with females (41), suggestive of a downregulation of Mrp4 by androgens. In contrast, androgens induced the abundance of MRP4 in prostate cancer cells (43) . Whether this is related to interorgan and/or interspecies differences needs to be defined. BCRP expression was found to be sex specific as well (44) and its activity is influenced by sex steroids, suggesting a role for the efflux pump in steroid metabolism (45) . We could recently support this hypothesis and showed presence and localization of BCRP in various steroid hormone producing organs together with potent inhibitory effects on BCRP activity by estradiol, progesterone, testosterone, and androstenedione (35) .
Dexamethasone is often used as a ligand for nuclear hormone receptors, including pregnane xenobiotic receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3), which are discussed in the next section. However, the synthetic hormone can also act through the glucocorticoid receptor without activating transcription factors. Glucocorticoid signaling to Mrp2 was recently demonstrated in killifish renal proximal tubules through a rapid increase in Mrp2-mediated transport after dexamethasone exposure (46) . Cortisol and triamcinolone acetonide exerted a similar effect, whereas cortisone, an inactive cortisol metabolite, was without effect. The glucocorticoid receptor mediated action was regulated through a non-genomic mechanism, because protein synthesis inhibition did not abolish the dexamethasone effect and neither did immunohistochemistry reveal any alterations in Mrp2 luminal membrane expression. This nongenomic action of dexamethasone corresponds to results from rat kidney where the glucocorticoid showed renoprotective effects against ischemia reperfusion injury (47). Furthermore, dexamethasone signaled to Mrp2 through c-Met, a receptor tyrosine kinase and its downstream effector pathway, MEK1/ 2, a protein ser/thr kinase. Blocking the receptor/ligand interaction and/or inhibition of tyrosine kinase activity are strategies for novel targeted therapies in oncology. The native ligand for c-Met, hepatocyte growth factor (HGF), showed identical effects, suggesting endogenous HGF is released upon dexamethasone treatment. HGF displays a complex program of proliferation and ontogenesis in a number of different cell types, including kidney. Moreover, HGF is involved in several in vivo and in vitro tumor cell invasions. Perturbation of HGF/c-Met signaling axis leads to enhanced signaling that occurs in a wide range of human cancers, and elevated c-Met signals are characteristic of aggressive tumors with poor prognosis (48) . Inhibition of Mrp2 by tyrosine kinase inhibitors could aid in cancer therapy, because the efflux pump may contribute to drug resistance in chemotherapy (7). On the other hand, chemicals that influence the tyrosine kinase pathway, such as tyrosine kinase inhibitors that block c-Met, may increase the sensitivity to xenobiotics and lead to reduced renal function associated with tyrosine kinase inhibitor treatment (49) . c-Met acts through the MEK1/2 signaling cascade, which in turn may phosphorylate and, thereby, activate ERK. It can be speculated that the increase in Mrp2 function caused by glucocorticoids and activating MEK1/2 and ERK1/2 signaling is an essential way by which renal cells cope with accumulating waste products of metabolism during stress.
Endothelin-1 and Calciotropic Hormones
An autocrine signaling pathway involving the vasoactive hormone, endothelin-1, that regulates P-gp and Mrp2 in response to several nephrotoxic agents in renal proximal tubules, was previously demonstrated (50, 51) . The signaling pathway was discovered originally in lower vertebrate, killifish renal tubules, but later demonstrated in rats in vivo and in MDCKII cells over-expressing human MRP2. Exposing killifish tubules to radiocontrast agents, aminoglycoside antibiotics, and certain heavy metals caused the following sequence of events: (1) release of endothelin (ET) to the medium, (2) activation of a basolateral ET B receptor, (3) activation of nitric oxide synthase (NOS), and generation of nitric oxide (NO), (4) activation of protein kinase C (PKC), and (5) reduction in P-gp-and Mrp2-mediated transport. Signaling appeared to be Ca 2+ dependent, because ET release was blocked by the Ca 2+ -channel blocker, nifedipine, and it was activated (in the absence of nephrotoxicants) by elevated medium Ca 2+ . The calciotropic hormones, parathyroid hormone, PTH-related protein, and stanniocalcin, were also found to interfere with ET-regulated Mrp2 activity through PKC and cGMP signaling (58) . Conversely, the results also pointed towards Ca 2+ -independent activation of NOS, suggesting involvement of iNOS that could be confirmed in rat studies (51) . In the long-term, however, luminal Mrp2 and P-gp activities and protein expression are increased 24 h after transient exposure to ET-1 or nephrotoxicants. Blocking the efflux pumps resulted in an enhancement of cell damage and necrosis, indicating that their upregulation during toxic stress is a prerequisite for survival (51) . An upregulation generally results from induced de novo synthesis of the transporter proteins or posttranscriptional regulation, which involves receptors and signaling pathways that alter their function (55, 72) . In support of a transcriptional regulation, increased gene expression levels of Abcb1b and Abcc2 were found in the kidney after nephrotoxic injury or in chronic renal failure (51, 63, 65) .
Nuclear Factorial Regulation of ABC Transporters Expressed in Kidney
Nuclear hormone receptor superfamily members are vital regulators of the adaptive response in physiological alterations. Some members of this superfamily of transcriptional regulators are ligand inducible and triggered by either xenobiotics or endogenous, most often lipophilic, substances. Steroid hormones are natural ligands and act by binding DNA as a homodimer. Differences in transporter expression and its function between males and females are explained by binding of circulating sex hormones to nuclear steroid hormone receptors (see "Steroid Hormones"). Other nuclear receptor superfamily members bind DNA as heterodimers with retinoid X receptor alpha (RXRα; NR2B1), such as the farnesoid X receptor (FXR; NR1H4), PXR, CAR, and the peroxisome proliferator-activated receptor alpha (PPARα; NR1C1). In mammalian liver, P-gp and Mrp2 expressions are induced through activation of PXR and CAR (60) . Although Mrp2 expression in the kidney can be regulated by PXR, the expression levels of this nuclear receptor in kidney appears to be low but with clear species differences (46) . Treatment of rats with PXR ligands decreased the expression of Mrp4 in the kidney, suggesting a negative regulation of this efflux pump by PXR (42) . No clear evidence was found for PXR, CAR, or FXR in regulating BCRP; neither was a role for PPARα found in regulating ABC transporters expressed in kidney.
The aryl hydrocarbon receptor (AhR) might be important in regulating MRP4 and BCRP transporters in the kidney (73, 74) . Binding of specific ligands to the AhR results in the formation of a heterodimer complex with the AhR (2), stability of mRNA (3), translation of mRNA into ABC proteins (4), phosphorylation of the transporters by protein kinases (5), or allosteric control by regulatory proteins (6) . Transporter abundancy in the membrane can also be regulated by modulating retrieval (7) or insertion (8) machineries for the ABC proteins. Scheme is adapted from (71) nuclear translocator, which, in turn, binds to dioxin responsive element sequences located in the promoter regions of target genes, hence, regulating transcription (75) . Activators of the AhR are diverse and include environmental contaminants (e.g., dioxins and polycyclic aromatic hydrocarbons), nutrients (e.g., flavanoids), endogenous metabolites (kynurenic acid and indoxyl sulphate), and drugs (statins). Just recently, AhR agonists have also been used in killifish renal proximal tubule to regulate protein expression of ABC transporters in kidney (76); however, information on AhRmediated regulation of drug transporters in human kidney is as yet still absent. Species differences, such as reported for AhR regulation in rodent kidneys compared with humans (77) , limit the ability to translate the findings across mammals, including humans. For instance the AhR-mediated BCRP regulation pathway in human intestinal cell lines could not be demonstrated in mouse cell lines (78) .
Recent studies by Aleksunes et al. (64) revealed involvement of the nuclear factor E2-related factor 2 (Nrf2) in regulating Mrp2 and Mrp4 in cisplatin-induced nephrotoxicity. This pathway is activated in conditions of oxidative stress and is presumably the most important route to promote cell survival in stress conditions. Inhibitor of Nrf2 (INrf2), also called Kelch-like ECH-associated protein 1 (Keap1), links Nrf2 to the ubiquitin ligase, Cul3-Rbx1, complex that ubiquitinates, and degrades Nrf2. Physiologically, cytosolic INrf2/Cul3-Rbx1 is continuously degrading Nrf2, but during stress conditions Nrf2 translocates to the nucleus after dissociating from INrf2. Subsequently, Nrf2 binds to the antioxidant response element and activates a number of defensive genes, such as NAD(P)H/quinone oxidoreductase 1, glutathione-S-transferases (GST), heme oxygenase 1, ubiquitination enzymes, and drug transporters. A crossreaction between Nrf2-and AhR-mediated signal transduction in regulating phase II enzymes have been reported (79) , but whether a similar cross-talk between the transcription factors exist in regulating ABC transporters remain to be elucidated.
Regulation of ABC Transporters in Kidney Failure
Acute Kidney Injury
Acute kidney injury (AKI) is one of the most frequently occurring clinical problems concerning the kidney, which is associated with a high morbidity and mortality, and complicates 5% of all hospital admissions. The acute loss of kidney function is often a result of renal tubular necrosis. Differential expression of ABC transporters in the kidney was detected during pathological circumstances, such as nephrotoxicity or ischemic injury. Cadmium-, cisplatin-, gentamicin-, and endotoxin-mediated renal damage are associated with elevated levels of P-gp, Mrp2, and Mrp4 (51, 72, 63, 62) . In most druginduced toxicities, oxidative stress pathways are involved as described under Nuclear factorial regulation of ABC transporters expressed in kidney.
Hartmann et al. (80) demonstrated increased urinary excretion of doxorubicin during endotoxemia in mice due to increased renal P-gp expression levels. The role of NO as an intermediate in the signaling pathways of P-gp (and also Mrp2) was derived from the endothelin-triggered pathways discovered in lower vertebrates. We suggested that generation of NO is a result of an induction in iNOS, which is under physiological conditions only weakly expressed in kidney proximal tubules. However, a remarkable induction in iNOS expression occurs in inflammatory conditions, e.g., in sepsis, endotoxemia, or in hypoxic renal injury (81) . NO upregulates P-gp during endotoxemic AKI in rats, through an NF-kBdependent pathway (61) . Moreover, TNF-alpha-mediated upregulation in P-gp involved TLR4 activation and NF-kB translocation, which apparently is independent of NO. This indicates that at least two pathways are involved in the regulation of renal P-gp expression during endotoxemia. Whether similar regulatory pathways take place in renal MRP2 activity remains to be determined.
The effect of NO on renal function was investigated further in healthy human volunteers during endotoxemia (82) . iNOS gene expression was highly induced after endotoxin administration accompanied by a marked increase in urinary NO metabolites excretion, which correlated strongly with the excretion of GST A1-1, a renal tubule injury marker. Blocking iNOS through aminoguanidine co-administration attenuated these effects, indicating that renal upregulation of iNOS and NO production result in nitrosative stress and renal injury. Whether drug transporters are functionally altered in human kidneys in inflammatory conditions needs to be defined.
Disturbances of homeostasis can induce coordinated changes of transporter expressions in remote organs as well. In liver injury, due to inflammation or ischemia-reperfusion injury, P-gp and Mrp2 expression levels were found to be reduced, whereas their expression levels in the kidney were upregulated (51, 83) . This adaptive interorgan response is possibly a compensatory mechanism to excrete detrimental waste products or stress factors during processes associated with liver failure. The differences in ABC transporter expressions between kidney and liver are likely to be related to variations in regulatory mechanisms. Sepsis-induced AKI for example, may cause clinical problems with drugs that depend on kidney function for their elimination and potentially are highly bound to plasma proteins. For some medicines, drug dosage adjustment will become mandatory in case of severe renal failure.
Chronic Renal Failure
In rats with chronic kidney disease (CKD), an induction in the expression of Mrp2 was found in the kidney, whereas no changes in expression levels of P-gp were found (65) . During CKD, human metabolism is highly disturbed leading to a progressive accumulation of metabolites that normally are excreted by the kidneys. Accumulation of predominantly small, protein-bound, organic molecules generates toxic concentrations of some of these so-called uremic toxins (84) . These biologically active uremic retention solutes fully depend on residual renal function for their elimination through secretion (85) . The basolateral uptake of uremic toxins in renal proximal tubule cells has been studied more intensely (3), however, far less is known about their urinary efflux for which MRP4 and BCRP may be important transporters. Both are involved in urinary secretion of urate (36, 86) , a uremic toxin responsible for the pathogenesis of gout and cardiovascular disease. The interaction of the uremic retention solutes hippuric acid, indoxyl sulfate and kynurenic acid with MRP4 and BCRP, and of indole-3-acetic acid and phenylacetic acid with MRP4 only was recently demonstrated (87) . The inhibition of transport by the uremic toxins occurred at clinically relevant concentrations, suggesting that this mechanism may contribute to the progression and the many complications of CKD. Targeting efflux pumps through regulatory pathways in renal failure by increasing their abundance may be a challenging approach to limit the progression.
ABC Transporters in Kidney Regeneration
Kidney tissue has a natural ability to recover and regenerate after acute damage despite the high susceptibility of the proximal tubule epithelium. Drug transporters might play a role in repair by controlling proliferation, migration and morphogenesis. As reviewed in (12) , ABC transport proteins were found to be upregulated in regeneration of diverse tissues, including liver, heart and skeletal muscle tissues, and actively protect cells via drug-independent mechanisms. In mice kidney tissue, a clear upregulation of P-gp and Bcrp was found after injury by ABC transporter expression profiling, suggesting a role for the efflux pumps in repair of damaged nephron segments (32) . Both transporters are not only present in epithelia but also highly expressed on a population of primitive bone marrow-derived stem cells with long-term repopulating capacities, termed side population (SP) cells. When expression of P-gp and BCRP is reduced the cell undergoes a phenotypic change, usually towards a more differentiated cell. This indicates that Pgp and BCRP possibly determine tissue regeneration through their differential expression on SP cells, which have been implicated in the remodeling of various tissues and organs, such as skeletal muscle, liver, and heart (12). Contraditory reports on the involvement of SP cells in renal regeneration have been published, leaving a conclusive answer still open (88) . A bone marrow reconstitution of wild-type, P-gp-or Bcrp-deficient mice origin in wild-type mice subjected to irradiation to destroy endogenous bone marrow, showed that transporter-deficient bone marrow transplantations protected wild type mice against ischemia-induced renal injury (18, 88) . This protection was likely a result of bone marrow-derived cells, because significantly more bone marrow-derived cells were detected in kidneys grafted with transporter-deficient bone marrow. Cell fusion of resident tubular cells with bone marrow cells was unlikely to have occurred, as shown by a gender mismatch study. It is likely that the protective mechanism resulted from an altered immune reaction, since bone marrow from P-gp-or Bcrp-deficient mice contained significantly more monocytes and granulocytes as well as early outgrowth endothelial progenitor cells, (88) . As these findings in ABC transporter knockout mice contradict the findings in humans with polymorphisms that lead to reduced or nonfunctional efflux pump variants, more research is essential to fully understand the renal protective mechanism in P-gp-or Bcrpdeficiency.
CONCLUSIONS AND PERSPECTIVES
Information on ABC transporter regulation in the kidney is sparse but insight into the processes regulating Pgp, the MRPs and BCRP is of relevance to reduce nephrotoxicity often associated with drug therapy. Especially during kidney failure, a high demand is put on renal tubule cells to eliminate accumulating products, as incomplete clearance of drugs and other potentially toxic agents, including products from normal metabolism/uremic toxins, leads to enhanced nephrotoxicity and systemic problems. Targeting regulatory pathways as therapeutic strategy to enhance renal xenobiotic excretion and reduce accumulation offers a nephroprotective mechanism relevant in conditions of reduced renal function.
The assembly of the efflux transporters is influenced by the ubiquitin-proteasome pathway. Modulation of endosomal retrieval or ubiquitination can regulate the change in the degradation rate of apical-surface-resident ABC transporters, thereby inducing their cell-surface expression and increasing their activity (89) (90) (91) (92) .
Furthermore, epigenetic mechanisms, such as DNA hypermethylation and histone modifications, may influence diverse cellular processes through gene silencing, and are a characteristic of cancer. Transporter activities may be influenced by these processes (93) , although nothing has been reported on epigenetic changes of ABC transporters expressed in the kidney.
Finally, a new emerging field in the regulation of not only transporter genes but also drug metabolizing enzymes and nuclear receptors, comprises the microRNAs, a family of short noncoding RNAs involved in the negative regulation of gene expression at the post-transcriptional level (94) . MicroRNAs can induce mRNA degradation by binding to the 3′-untranslated region of the target gene or result in repression of protein translation. A few hundred microRNAs have been identified in various organisms, and it is estimated that 50% of the protein-coding genes is regulated through these microRNAs, with critical roles in the kidney (95) . Although no specific examples have been reported for the regulation of ABC transporters in the kidney, microRNAs will undoubtedly have a major impact on the renal drug transporter field. In other tissues, regulation of P-gp, MRP2, MRP4, and BCRP by microRNAs, directly or indirectly through nuclear receptors or factors (including AhR, Nrf2, RXR, and PPARs), was convincingly demonstrated (94, 96, 97) . MicroRNAs occasionally cause histone modification or DNA methylation of promoter sites as well, thereby affecting the target genes expression levels. The microRNAs are important in kidney development and regulate physiological processes and may also play a role in the pathogenesis of kidney diseases, such as drug-induced AKI and CKD (98) . In addition, microRNAs can serve a role as biomarkers in kidney disease (99) . Modulators of microRNAs, such as antagomirs, a novel class of chemically engineered oligonucleotides, have been developed to enable specific targeting, which influences the mechanisms that underlie disease initiation or progression (100) . Clinical applications of this innovative approach are promising, including targeting kidney diseases but caution should be taken as microRNAs or their inhibition can become oncogenic.
